Literature DB >> 27118189

Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?

Felix M Mottaghy1,2, Alexander Heinzel3, Frederik A Verburg3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27118189     DOI： 10.1007/s00259-016-3389-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  20 in total

1.  Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Authors:  Tobias Maurer; Jürgen E Gschwend; Isabel Rauscher; Michael Souvatzoglou; Bernhard Haller; Gregor Weirich; Hans-Jürgen Wester; Matthias Heck; Hubert Kübler; Ambros J Beer; Markus Schwaiger; Matthias Eiber
Journal:  J Urol       Date:  2015-12-09       Impact factor: 7.450

2.  (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

Authors:  Francesco Ceci; Christian Uprimny; Bernhard Nilica; Llanos Geraldo; Dorota Kendler; Alexander Kroiss; Jasmin Bektic; Wolfgang Horninger; Peter Lukas; Clemens Decristoforo; Paolo Castellucci; Stefano Fanti; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-15       Impact factor: 9.236

3.  ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors:  Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

4.  (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.

Authors:  Emre Demirci; Meltem Ocak; Levent Kabasakal; Clemens Decristoforo; Zübeyir Talat; Metin Halaç; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-23       Impact factor: 9.236

5.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

6.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

7.  MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.

Authors:  Constantinos Zamboglou; Gesche Wieser; Steffen Hennies; Irene Rempel; Simon Kirste; Martin Soschynski; Hans Christian Rischke; Tobias Fechter; Cordula A Jilg; Mathias Langer; Philipp T Meyer; Michael Bock; Anca-Ligia Grosu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-23       Impact factor: 9.236

8.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.

Authors:  A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-24       Impact factor: 9.236

9.  PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.

Authors:  Frederik L Giesel; H Fiedler; M Stefanova; F Sterzing; M Rius; K Kopka; J H Moltz; A Afshar-Oromieh; P L Choyke; U Haberkorn; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-11       Impact factor: 9.236

10.  Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer.

Authors:  F L Giesel; F Sterzing; H P Schlemmer; T Holland-Letz; W Mier; M Rius; A Afshar-Oromieh; K Kopka; J Debus; U Haberkorn; C Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-14       Impact factor: 9.236
View more
  9 in total

1.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

2.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

3.  Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.

Authors:  Spencer C Behr; Rahul Aggarwal; Henry F VanBrocklin; Robert R Flavell; Kenneth Gao; Eric J Small; Joseph Blecha; Salma Jivan; Thomas A Hope; Jeffry P Simko; John Kurhanewicz; Susan M Noworolski; Natalie J Korn; Romelyn De Los Santos; Matthew R Cooperberg; Peter R Carroll; Hao G Nguyen; Kirsten L Greene; Beatrice Langton-Webster; Clifford E Berkman; Youngho Seo
Journal:  J Nucl Med       Date:  2018-11-21       Impact factor: 10.057

4.  68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Authors:  Alexander Heinzel; Dima Boghos; Felix M Mottaghy; Florian Gaertner; Markus Essler; Dirk von Mallek; Hojjat Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-29       Impact factor: 9.236

5.  99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.

Authors:  Burçak Yılmaz; Selçuk Şahin; Nurhan Ergül; Yunus Çolakoğlu; Halil Fırat Baytekin; Doğukan Sökmen; Volkan Tuğcu; Ali İhsan Taşçı; Tevfik Fikret Çermik
Journal:  Ann Nucl Med       Date:  2022-04-15       Impact factor: 2.668

Review 6.  Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?

Authors:  Simone Albisinni; Julien Sarkis; Romain Diamand; Cosimo De Nunzio
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-09-09       Impact factor: 5.455

7.  Incremental Value of Ga-68 Prostate-Specific Membrane Antigen-11 Positron-Emission Tomography/Computed Tomography Scan for Preoperative Risk Stratification of Prostate Cancer.

Authors:  U N Pallavi; Sanjay Gogoi; Parul Thakral; Vindhya Malasani; Kanchan Sharma; Divya Manda; Subha Shankar Das; Vineet Pant; Ishita Sen
Journal:  Indian J Nucl Med       Date:  2020-03-12

8.  18F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer.

Authors:  Zhuonan Wang; Anqi Zheng; Yunxuan Li; Weixuan Dong; Xiang Liu; Wang Yuan; Fan Gao; Xiaoyi Duan
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

Review 9.  Clinical perspectives of PSMA PET/MRI for prostate cancer.

Authors:  Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.